We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Shortened p53 Protein Promotes Tumor Growth by Modulating Mitochondrial Function

By LabMedica International staff writers
Posted on 20 Dec 2016
A shortened version of the p53 protein - caused by a mutation in the TP53 tumor suppressor gene – has been found to promote rather than impede tumor growth.

The gene that encodes p53 is the most frequently mutated gene found in many types of cancer, and notably in most late-stage cancers. More...
While most p53 gene mutations prevent p53 from being functional, investigators at Cold Spring Harbor Laboratory (NY, USA) discovered a variety of mutated p53 protein that actually promoted tumor growth.

The investigators reported in the October 19, 2016, online edition of the journal eLife that p53 proteins truncated after the sixth protein-coding segment (exon-6) no longer functioned as tumor suppressors but instead promoted cancer by directly altering the functions of mitochondria. The version of p53 encoded by TP53 exon-6 truncating mutations lacked roughly half of the domains of the full-length p53 protein, specifically the domains that enable full-length p53 to enter the cell nucleus and bind DNA.

TP53 exon-6 truncating mutations occurred at higher than expected frequencies and produced proteins that lacked canonical p53 tumor suppressor activities but instead promoted cancer cell proliferation, survival, and metastasis. Functionally and molecularly, these p53 mutants resembled the naturally occurring alternative p53 splice variant, p53-psi. Due to their similarity to p53-psi, these mutants were able to localize to the mitochondria where they promoted tumor phenotypes by binding and activating the mitochondria inner pore permeability regulator protein, Cyclophilin D (CypD).

"Remarkably, despite 40 years of research and over 80,000 publications on p53, our new findings show that it still holds mystery and promise," said senior author Dr. Raffaella Sordella, an associate professor at Cold Springs Harbor Laboratory. "It seems that by changing mitochondrial function, the variants are priming cells to reprogram themselves. These mutations are strong candidates for targeting by precision medicine. The frequency of exon-6 truncating mutations in fact is comparable to other precision medicine targets such as the EGFR oncogenic-mutations found in lung cancer. We have begun discussing with several pharmaceutical companies ways in which we can use our newly gained knowledge to develop treatments that will make a positive difference for many cancer patients."

Related Links:
Cold Spring Harbor Laboratory



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.